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OBJECTIVES The purpose of this study was to evaluate an implantable cardioverter-defibrillator (ICD)
incorporating biventricular pacing.
BACKGROUND Biventricular pacing improves the symptoms of heart failure, a frequent problem in ICD
recipients.
METHODS This prospective multicenter study evaluated the safety and efficacy of an ICD with
biventricular pacing.
RESULTS A total of 84 patients with a standard ICD indication, symptomatic heart failure, left
ventricular (LV) ejection fraction 35% and a QRS duration 130 ms were included in the
trial. In 81 of 84 patients the LV lead was successfully implanted. Patients significantly
improved in the 6-min hall-walk test (baseline 304 131 m, three months 397 142 m, p
0.001), quality of life (baseline 38.9  21.2, three months 26.5  21.2, p  0.001) and the
New York Heart Association (NYHA) classification (baseline 2.8  0.6, three months 2.2 
0.5). Left ventricular end-diastolic (from 79.6  13.0 mm to 73.6  12.9 mm, p  0.002)
and end-systolic (from 68.3  13.5 mm to 63.9  12.9 mm, p  0.001) diameter decreased,
and fractional shortening increased (from 16  6% to 18  6%, p  0.018). Of the patients
26 experienced 472 episodes of spontaneous sustained ventricular tachyarrhythmias. All
episodes were successfully terminated except for 16 episodes occurring in a patient with
incessant ventricular tachycardia. Biventricular antitachycardia pacing was more effective than
right ventricular antitachycardia pacing (p  0.001). During follow-up (median 185 days,
range 12 to 344 days) five patients died from progressive heart failure.
CONCLUSIONS Incorporating biventricular pacing in an ICD is feasible and leads to an improvement of heart
failure symptoms. Therefore, this therapy may become an option for patients who need ICD
therapy in the presence of severe heart failure. (J Am Coll Cardiol 2002;39:790–7) © 2002
by the American College of Cardiology Foundation
Treatment with an implantable cardioverter-defibrillator
(ICD) is an accepted mode of treatment in patients with
life-threatening ventricular tachyarrhythmias (1). Subgroup
analysis in the Antiarrhythmics Versus Implantable Defi-
brillators (AVID) (2) study has shown that patients with
severely depressed left ventricular (LV) function have the
largest benefit from ICD treatment. Although ICD treat-
ment in patients at risk prolongs life, it does not improve
quality of life or the symptoms of heart failure. In recent
years it has been shown in both acute and long-term studies
that biventricular pacing improves hemodynamic parame-
ters and symptoms in heart failure patients (3–7). However,
the separate implantation of an ICD and a dual-chamber
pacemaker capable of biventricular pacing carries additional
risks owing to the extracardiac leads and possible interac-
tions between devices (8), similar to what has been de-
scribed for VVI and DDD pacemakers (9,10). The present
study reports the initial experience with an ICD incorpo-
rating ventricular resynchronization therapy.
METHODS
Study design. This was a prospective study in patients
indicated for ICD therapy because of symptomatic sus-
tained ventricular tachycardia (VT) and/or survival of car-
diac arrest. In addition, patients were required to have
symptomatic heart failure despite appropriate heart failure
therapy, with a LV ejection fraction (LV angiogram or
echocardiography)35% and an LV end-diastolic diameter
above 55 mm (echocardiography). The QRS duration had
to be 130 ms. All patients participated voluntarily and
signed a written, informed consent approved by the study
center’s Institutional Review Board.
Device description. The device implanted in this study
was the InSync 7272 ICD (Medtronic Inc., Minneapolis,
Minnesota), which is capable of delivering ICD therapies
and cardiac resynchronization therapy. It is based on the
Medtronic GEM models 7271 and 7273 ICDs and the
InSync model 8040 device. The characteristics of the GEM
models 7271 and 7273 have been described elsewhere
(11,12). The device has a special five-port header for
connection of four leads, which have three pacing electrodes
(one atrial lead, one right ventricular [RV] lead and the LV
lead) and two defibrillation coils (Fig. 1). Cardiac resyn-
chronization and antitachycardia pacing (ATP) can be
programmed to right, left or biventricular stimulation. It is
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important to note that both ventricular sensing and detec-
tion remain on the right side; hence, both sensing and
detection in the InSync ICD are unchanged from ICD-only
systems.
Study protocol. Prior to implantation of the device, patient
assessment included: New York Heart Association
(NYHA) classification and echocardiography for determi-
nation of the LV systolic and diastolic diameter, LV ejection
fraction and presence and severity of mitral regurgitation.
Patients performed a 6-min hall-walk test and completed
the Minnesota Living With Heart Failure Questionnaire
(13,14).
OPTIMIZING OF THE ATRIOVENTRICULAR (AV) DELAY. The
AV optimization was obtained using Doppler echocardiog-
raphy. First, the device was programmed to 40 beats/min to
assure an intrinsic sinus rate. The sensed AV delay was
programmed to 200 ms. In this setting, mitral valve closure
is delayed to the end of the A-wave. The sensed AV interval
was decreased in steps of 20 ms until the mitral valve
Doppler signal caused truncation of the A-wave. Finally,
the sensed AV interval was increased in steps of 10 ms to
ensure that the mitral valve closure Doppler signal coincided
with or occurred shortly after the end of the A-wave.
Patients were seen when discharged from the hospital and
on an outpatient basis at one and three months of follow-up.
At the follow-up visits, the 6-min hall-walk test was
repeated as was the Minnesota Living With Heart Failure
Questionnaire; an echocardiogram was obtained and the
severity of heart failure (NYHA classification) was assessed.
If necessary, the AV interval was reprogrammed. Arrhyth-
mic episodes were retrieved from the device’s memory and
classified by the local investigator. All episodes were rean-
alyzed independently by investigators V. K. and B. K. (see
Appendix), who were both unaware of the patient’s symp-
toms at the time of the arrhythmic episode and the
classification of the episode by the local investigator. The
criteria used have been published elsewhere (15). Effective
termination of an episode was defined as the detection of
eight consecutive paced or sensed cardiac cycles greater than
or equal to the ventricular tachycardia detection interval that
were not classified as VT or ventricular fibrillation (VF).
Statistical analysis. The means and standard deviations for
hall-walk distance and quality of life were calculated for the
baseline, one-month and three-month time points. To test
for changes in these parameters with cardiac resynchroni-
zation therapy, paired t tests were used to compare the
results at one month and three months with baseline values.
Two-sided tests with a significance level of 0.05 were used.
Both the number and the percent of patients with each
NYHA classification (I to IV) were determined for the
baseline, one-month and three-month time points. To test
for changes in NYHA functional class with cardiac resyn-
chronization therapy, paired comparisons using the McNe-
mar test for significant change were used to compare the
one-month and three-month results with baseline values.
Two-sided tests with a significance level of 0.05 were used.
The percent of episodes successfully terminated was
estimated using a generalized estimating equations model
accounting for correlation within clusters of binary re-
sponses. A two-sided 95% confidence interval was also
Abbreviations and Acronyms
ATP  antitachycardia pacing
AV  atrioventricular
AVID  Antiarrhythmics Versus Implantable
Defibrillations study
FVT  fast ventricular tachycardia
ICD  implantable cardioverter-defibrillator
LV  left ventricular
NYHA  New York Heart Association
RV  right ventricular
VF  ventricular fibrillation
VT  ventricular tachycardia
Figure 1. Typical chest radiograph of a patient with an implantable cardioverter-defibrillator with a right atrial lead, a dual-coil ventricular lead and a left
ventricular lead. The left ventricular lead is implanted in a posterolateral vein. The right part of the figure shows a chest radiograph three days after
implantation of the system; the left part shows the ap chest radiograph three months of biventricular pacing; note that the cardiothoracic ratio was reduced.
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determined. The Kaplan-Meier method was used to esti-
mate overall survival from all causes of death.
RESULTS
Patient population. Eighty-four patients were enrolled in
this study. The InSync 7272 ICD was successfully im-
planted in 81 patients (96.4%). Cardiac resynchronization
therapy was not possible in three patients. These three
patients are not included in all data analysis except for the
analysis of the ICD and/or lead-associated complications.
Patients included in the study are summarized in Table 1. A
total of 85% of patients were on angiotensin-converting
enzyme inhibitors, and 54% of patients received a beta-
blocker at baseline. Left ventricular ejection fraction was
25  7%, mean QRS duration was 170  30 ms and the
mean LV end-diastolic diameter was 79.6  13.0 mm.
Paroxysmal atrial fibrillation was documented in 19
patients (23%); 10 patients (12%) had a history of atrial
flutter. Symptomatic sinus bradycardia was present in 10
patients (12%), 27 patients (33%) had an AV block of I
degree and 7 patients (9%) had an AV block of II or III
degree.
Implantation of the ICD and leads. Standard commer-
cially available leads were used in the right atrium and the
RV. Ten patients received the InSync 7272 ICD as a
replacement device of an earlier implanted standard ICD. In
one patient the implantation was a replacement of a previ-
ous cardiac resynchronization system that did not include
ICD therapy.
The primary LV leads used in this study were the
Medtronic Attain Model 2187 LV lead and the Medtronic
Attain CS Model 2188. In five patients, other commercially
available leads were used; one patient received an investiga-
tional lead and one system was a replacement of a previous
cardiac resynchronization system with ICD therapy. A
guiding sheath (Medtronic Attain Model 6216) was used to
cannulate the coronary sinus, and a balloon catheter
(Medtronic Attain Model 6215) was used to obtain an
angiogram of the coronary sinus and the ventricular venous
structure. Placement of the RV and LV leads was performed
according to recently published suggestions with biventricu-
lar pacemakers (16). The location of the LV lead was
determined from the intraoperative venogram. In the ma-
jority of cases the LV lead was forwarded to a posterior-
lateral vein (n  37, 46%) or a lateral vein (n  26, 32%).
After implantation of the leads, mean QRS duration de-
creased from 170  30 ms to 158  34 ms (p  0.001).
Total procedure time was 192  84.1 min (range 69 to
480 min), mean time for the placement of the LV lead was
77 64.5 min (range 2 to 402 min). Mean fluoroscopy time
was 40.0  30.7 min, with a range from 1 to 149 min. Of
84 patients, 77 were successfully implanted at first at-
tempted (92%). An additional four patients were success-
fully implanted following a second attempt.
The three failures to implant an LV lead were due to
inability to cannulate the coronary sinus in one patient, LV
lead dislodgement while retracting the guiding catheter in
one patient and in another patient the procedure was
stopped after perforation of the coronary sinus (Table 2).
In four patients a second LV lead implantation attempt
Table 1. Characteristics of Patients Who Received the Device
Number of patients n  81
Gender Women, n  7 (9%)
Men, n  74 (91%)
Age (yrs) 63.8  8.8 (41 to 79)
Underlying cardiovascular disease* Coronary artery disease, n  46
(57%)
Dilative cardiomyopathy, n  34
(42%)
Valvular heart disease, n  17
(21%)
LV ejection fraction 25  7%
LV end-diastolic diameter 71  11 mm
QRS duration 170  30 ms
NYHA classification NYHA II, n  26 (32%)
NYHA III, n  48 (59%)
NYHA IV, n  7 (9%)
Cardiovascular medication ACE inhibitors, n  69 (85%)
Diuretics, n  44 (54%)
Nitrates, n  25 (31%)
Digitalis, n  26 (32%)
Anticoagulants, n  45 (56%)
Beta-blockers, n  44 (54%)
Antiarrhythmics, n  47 (58%)
Supraventricular
tachyarrhythmias*
Paroxysmal atrial fibrillation,
n  19 (23%)
Chronic atrial fibrillation, n  5
(6%)
Atrial flutter, n  10 (12%)
Ventricular tachyarrhythmias* Sustained VT, n  52 (64%)
Ventricular fibrillation/flutter,
n  33 (41%)
*Not exclusive.
ACE  angiotension-converting enzyme; LV  left ventricular; NYHA  New
York Heart Association; VT  ventricular tachycardia.
Table 2. Complications Associated With the Implantation of
the Device (Peri-Implant) or During Follow-Up
(n)
Peri-implant complications (n  84)
Cardiac perforation/coronary sinus dissection 4
Unable to position LV lead 3
Hematoma requiring drainage 3
Pneumothorax 2
Dislodgement of the LV lead 1
Hematothorax 1
Pulmonary edema 1
Pneumonia 1
Complications during follow-up (n  84)
LV lead dislodgement
With loss of capture 2
Without loss of capture 4
Infection of the ICD and/or lead 2
Stimulation of the diaphragm 1
Device migration 1
Right atrial lead dislodgement 1
All numbers refer to the 84 patients in whom implantation of the biventricular device
was attempted.
ICD  implantable cardioverter-defibrillator; LV  left ventricular.
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was necessary owing to one perforation at the os of the
coronary sinus with the LV lead, inability to cannulate the
coronary sinus in two cases and no specific explanation in
one case. In these four cases the LV lead was successfully
implanted in the second attempt. Dissection of the coronary
sinus was seen in two patients not requiring further therapy.
A pneumothorax occurred in three cases, requiring drain-
age of the pleural cavity in two cases; one patient also had a
hematothorax, requiring drainage of the pleural cavity.
Effect of biventricular pacing on the symptoms of heart
failure. As outlined in the previous text, patients performed
a 6-min hall-walk test and completed a quality of life
questionnaire at baseline, one month, three months and six
months of follow-up. Severity of heart failure was assessed
by the treating physician at each visit using the NYHA
classification.
A significant (p  0.001) improvement in the 6-min
hall-walk test was seen at both follow-up visits as compared
to baseline (Table 3). Walking distance increased from
304  131 m to 390  137 m (n  72) at one month and
from 319  156 m to 393  143 m (n  56) at three
months of follow-up. Nine patients at baseline, three
patients at one month and no patient at three months of
follow-up were unable to perform the test due to heart
failure. Severity of heart failure was an important predictor
of the improvement in the walking distance. The NYHA
functional class III/IV heart failure patients had a significant
(p  0.001) improvement in the hall-walk test, whereas
NYHA functional class II patients did demonstrate an
improvement in hall-walk distance that did not reach
statistical significance (Table 3).
Table 3 shows the results of the Minnesota Living With
Heart Failure Quality of Life Assessment. The paired
comparison among baseline, one month and three months
of follow-up is demonstrated for all patients, NYHA
functional class II patients and NYHA functional class
III/IV patients. A significant (p  0.001) improvement in
quality of life was shown for NYHA functional class III/IV
patients. Patients with NYHA functional class II heart
failure had an almost unchanged quality-of-life score.
Figure 2 shows the effect of biventricular pacing on the
severity of heart failure symptoms. Mean NYHA classifica-
tion improved from 2.8  0.6 to 2.3  0.5 at one month
and 2.2  0.5 at three months. Dividing the patient
population by the severity of heart failure at baseline, it
became evident that 67% of the NYHA functional class
III/IV patients improved by at least one NYHA class,
whereas 85% of the NYHA functional class II patients
remained unchanged.
Effects of biventricular pacing of LV function. With
biventricular pacing, LV end-diastolic (p  0.002) and
end-systolic (p  0.001) diameter decreased significantly
(Table 4). Fractional shortening was significantly improved
with biventricular pacing (p  0.018). Again, the effects
were more pronounced and reached statistical significance
only for patients with NYHA functional class III and class
IV heart failure at baseline. However, even in NYHA
functional class II patients, a consistent trend toward an
improvement with biventricular pacing was seen.
Efficacy of therapy for spontaneous ventricular tachy-
arrhythmias. A total of 472 episodes (26 patients) were
appropriately detected as VT or VF, 339 episodes in 17
patients were detected in the VT zone, 107 episodes in 8
patients in the fast ventricular tachycardia (FVT) zone and
26 episodes in 8 patients in the VF zone. All ventricular
tachyarrhythmias were correctly identified; hence, sensitivity
for ventricular tachyarrhythmias was 100%. Double count-
ing of sensed events did not occur; thus, inappropriate
therapies due to double counting were not applied.
One patient experienced 27 VT episodes, 16 were not
successfully terminated as the patient was experiencing
incessant VT. All other episodes were successfully termi-
nated by the device.
Twenty-three patients had a total of 431 episodes in
Table 3. Effects of Ventricular Resynchronization Therapy on the Symptoms of Heart Failure: All Parameters Are Given at Baseline
and at a Follow-Up of One Month and Three Months, Respectively
1 Month* 3 Months*
Baseline 1 Month p Value Baseline 3 Months p Value
QOL NYHA functional class II 22.3  14.2 20.6  18.4 NS 22.1  14.8 21.5  17.5 NS
(n  23) (n  19)
QOL NYHA functional class III/IV 46.2  19.9 25.0  20.8 0.001 45.4  19.6 28.5  22.4 0.001
(n  53) (n  49)
QOL all 38.9  21.2 23.7  20.1 0 38.9  21.1 26.5  21.2 0.001
(n  76) (n  68)
6-min walk test NYHA functional class II 386  134 434  122 0.09 418  189 475  151 NS
(n  19) (n  19)
6-min walk test NYHA functional class III/IV 262  108 m 367  141 0.001 268  112 357  122 m 0.001
(n  53) (n  37)
6-min walk test all 304  131 m 390  137 m 0.001 319  156 397  142 m 0.001
(n  72) (n  56)
Values are divided by patients with New York Heart Association (NYHA) functional class III/IV heart failure at baseline and patients with NYHA functional class II heart failure
at baseline. The number of patients is shown in parentheses. A p value 0.1 is considered nonsignificant (NS).
*Numbers refer to paired tests only.
QOL  quality of life (Minnesota Living With Heart Failure Questionnaire [14]).
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which ATP therapies were applied (Table 5). Sixteen
patients were programmed to RV ATP, and nine patients
were programmed to biventricular ATP. Two patients
initially programmed to RV ATP were reprogrammed to
biventricular ATP, which was significantly more effective as
compared to RV ATP for all episodes in the VT zone (p 
0.0001).
In addition, there was a trend for a higher efficacy of
biventricular ATP in the FVT zone and fewer episodes that
were accelerated by ATP if biventricular ATP was used.
Mean cycle length of the ventricular tachyarrhythmias
treated by biventricular pacing was longer (389  55 ms) as
compared to ventricular tachyarrhythmias treated with RV
ATP (367  44 ms, difference NS). However, even after
correcting for cycle length of the VT and the type of ATP
(ramp/burst), biventricular ATP was significantly (p 
0.01) more effective than RV ATP.
Complications associated with the ICD and the lead
system during follow-up. A total of 10 patients out of 84
experienced 11 complications associated with the ICD
and/or the lead system during follow-up (Table 2): The
most frequent complication occurring in six patients was
dislodgement of the LV lead. This was associated with loss
of capture in two cases and without loss of capture in four
cases. The lead was repositioned in three patients and
removed in three patients as well.
Figure 2. Effect of biventricular pacing on the New York Heart Association (NYHA) classification. Patients are grouped according to the severity of heart
failure at baseline (NYHA functional class II vs. NYHA functional class III/IV) and follow-up (FU) visit (1-month follow-up visit vs. 3-month follow-up
visit). The majority of patients in NYHA functional class II at baseline remained unchanged during follow-up. This is in contrast to patients with NYHA
class III/IV heart failure at baseline; 35 patients showed an improvement of at least 1 NYHA functional class at both follow-up visits.
Table 4. Echocardiographic Parameters: All Parameters Are Given at Baseline and at a Follow-Up of One Month and
Three Months, Respectively
1 Month* 3 Months*
Baseline 1 Month p Value Baseline 3 Months p Value
LVEDD NYHA functional class II 75.7  9.7 67.4  24.6 NS 69.9  11.3 69.8  11.9 NS
(n  9) (n  16)
LVEDD NYHA functional class III/IV 81.4  14.1 75.9  12.4 0.01 75.2  13.8 70.6  13.5 0
(n  20) (n  38)
LVEDD all 79.6  13.0 73.3  17.1 0.025 73.6  13.2 70.4  12.9 0
(n  29) (n  54)
LVESD NYHA functional class II 63.6  10.2 54.9  23.6 NS 59.5  11.5 57.3  12.5 NS
(n  8) (n  14)
LVESD NYHA functional class III/IV 70.3  14.4 67.2  10.9 NS 65.6  13.2 59.8  14.0 0.001
(n  19) (n  36)
LVESD all 68.3  13.5 63.5  16.3 0.083 63.9  12.9 59.1  13.5 0.001
(n  27) (n  50)
FS NYHA functional class II 18  6 18  10 NS 16  6 20  7 NS
(n  8) (n  14)
FS NYHA functional class III/IV 15  7 13  3 NS 14  6 17  6 0.068
(n  19) (n  36)
FS all (n  50) 16  6 15  6 NS 15  6 18  6 0.018
(n  27) (n  50)
Values are divided by patients with New York Heart Association (NYHA) functional class III/IV heart failure at baseline and patients with NYHA functional class II heart failure.
Diameters are given in millimeters; fractional shortening (%) was determined in the short parasternal axis. The number of patients is shown in parentheses. A p value of 0.1 is
considered nonsignificant (NS).
*Numbers refer to paired tests only.
FS  fractional shortening; LVEDD  left ventricular end-diastolic diameter; LVESD  left ventricular end-systolic diameter.
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Infection of the ICD and/or lead system was observed in
two patients (2.5%), leading to explanation of the system. In
one patient infection occurred after an unsuccessful attempt
to reposition the LV lead. The second patient with an
infection of the ICD and/or lead system had an ICD with
dual-chamber pacing implanted, because implantation of
the LV lead was unsuccessful.
Survival during follow-up. During a mean follow-up of
178 days (range 12 days to 344 days, median 185 days) five
patients died. In all cases, death was classified as nonsudden
cardiac death not associated with the device or the implan-
tation procedure. Survival at three and six months was 96 
2%. One patient received a heart transplant after an un-
eventful follow-up of 67 days.
DISCUSSION
This study presents the initial experience with an ICD
capable of ventricular resynchronization therapy in patients
with severe heart failure.
Effect of biventricular pacing on the symptoms of heart
failure. Cardiac resynchronization therapy resulted in a
significant improvement in quality of life, symptoms of
heart failure and LV dimensions (Tables 3 and 4, Fig. 2).
Patients with NYHA functional class III/IV heart failure
had the largest benefit from biventricular pacing. Therefore,
this study strongly supports current recommendations to
implant a system with biventricular pacing in patients with
severely depressed LV function and NYHA functional class
III or IV heart failure (3). However, even patients in NYHA
functional class II heart failure showed an improvement in
the 6-min hall-walk test; studies with a longer follow-up are
still necessary to define the potential benefit of biventricular
pacing in these patients.
Detection of ventricular tachyarrhythmias. The electro-
grams recorded via the LV lead are not used for detection,
thus effectively preventing the possibility of double count-
ing. Hence, detection in the InSync 7272 ICD is unchanged
to detection in standard ICDs. In the Contak ICD, double
counting occurs when the two electrograms obtained from
the right and left ventricle are fed into a single amplifier.
This leads to inappropriate therapy in up to 14% of patients,
usually in the situation of sinus tachycardia with spontane-
ous AV conduction (17). However, double counting in the
Contak ICD occurs as well during VT (18).
ATP efficacy. The site of stimulation may modify the
ability of a stimulated impulse to enter the re-entry circuit
and terminate VT (19). With biventricular pacing, two
distinct pacing sites are used; this might enhance the ability
to effectively terminated VT by ATP. This study showed
that biventricular ATP was more effective than RV ATP
(Table 5), and a trend was seen that biventricular pacing did
result in fewer accelerations than RV ATP.
In a recent study with the Contak ICD, biventricular
pacing was not significantly more effective than RV ATP.
However, the control group in this study consisted of a
patient population that received an ICD with VVI or DDD
pacing. No data are presented in regard to the patient
population included in the control group (20). Thus, a
prospective study, including many more patients and epi-
sodes, is necessary to answer the question of whether
biventricular ATP is more effective than RV ATP.
A further important question is whether biventricular
pacing affects the incidence of sustained ventricular tachy-
arrhythmias. Data from the beta-blocker studies support the
concept that improving heart failure reduces sudden death,
suggesting that the incidence of sustained ventricular tachy-
arrhythmias is decreased (21). Two smaller studies using
biventricular pacing have shown positive effects on the
incidence of ventricular arrhythmias (22,23). In the present
study, 26 patients (33%) experienced at least one episode of
Table 5. Efficacy of Antitachycardia Pacing
Right Ventricular
ATP
Biventricular
ATP
p
Value
FVT
Number of episodes n  50 (6 patients) n  57 (6 patients) NA
Number of successfully terminated
episodes
n  31 (62%) n  43 (75%) NS
Number of accelerated episodes n  15 (30%) n  9 (16%) NS
Number of episodes with ATP failure n  4 (8%) n  5 (9%) NS
VT
Number of episodes n  154 (n  12 patients) n  170 (n  7 patients) NA
Number of successfully terminated
episodes
n  123 (80%) n  163 (96%) 0.0001
Number of accelerated episodes n  8 (5%) n  3 (2%) NS
Number of episodes with ATP failure n  23 (15%) n  4 (2%) 0.0001
FVT/VT
Number of episodes n  204 (n  16 patients) n  227 (9 patients) NA
Number of successfully terminated
episodes
n  154 (76%) n  206 (91%) 0.0001
Number of accelerated episodes n  23 (11%) n  12 (5%) 0.051
Number of episodes with ATP failure n  27 (13%) n  9 (4%) 0.003
ATP  antitachycardia pacing; FVT  fast ventricular tachycardia zone; VT  ventricular tachycardia zone.
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spontaneous sustained VT or VF, a finding similar to the
recently published data with an ICD with dual-chamber
pacing, where 96 (32%) of 300 patients experienced at least
one episode during a mean follow-up of 1.7 months (24).
Implantation of the system. The implantation of the LV
lead can be time-consuming. It has been shown with the
same LV lead that failure rate drops with the number of
leads that a center has implanted. However, tools to implant
LV leads need improvement before cardiac resynchroniza-
tion therapy will be widely applied (25). Initial experience
with new “over the wire” leads is promising (26,27).
The long procedural duration may have contributed to
the two infections. Predictors of operative complications are
the severity of heart failure, the surgical environment, the
duration of the intervention and diabetes. Two risk factors
were obviously present in our patients: long procedural
duration and severe heart failure (28).
Hematoma was another complication seen in three pa-
tients (3.7%); all three patients were on anticoagulant
therapy at the time of bleeding. In the InSync 7272 ICD
study population, 56% of patients were on anticoagulant
therapy at baseline as compared to 21% of patients in the
AVID study, where a 2.6% risk of bleeding was reported
(1).
Study limitations. The major weakness of the study was
the lack of a control group of patients with a comparable
stage of heart failure receiving ICD therapy. From this
study it is unknown to what extent an ICD with biventricu-
lar pacing improves symptoms and/or the prognosis in heart
failure patients in comparison to a control group. However,
the aim of the present study was to gain initial experience
with an ICD system capable of ventricular resynchroniza-
tion therapy. This study offers important information con-
cerning the initial experience with the system and adds
important data to the knowledge on ventricular resynchro-
nization therapy.
Conclusions. Ventricular resynchronization therapy and
ICD therapy can be safely achieved using the InSync 7272
ICD system. Biventricular ATP was more effective than RV
ATP. The NYHA functional class III/IV heart failure
patients showed a significant improvement in functional
status, LV dimensions and quality of life. The results
obtained in NYHA functional class II patients are encour-
aging. Therefore, an ICD incorporating ventricular resyn-
chronization therapy may be an important option for
patients with severe heart failure who need ICD treatment.
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